## Supplementary Figures for

Synthetic Alkyl-Ether-lipid promotes TRPV2 Channel trafficking trough PI3K/Akt-Girdin Axis in cancer cells and increases mammary tumor volume.

Gueguinou Maxime and al.,

Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France.

Corresponding author Marie Potier-Cartereau

Email: marie.potier-cartereau@univ-tours.fr

Inserm UMR 1069, Nutrition Croissance Cancer, Faculté de Médecine, Université de Tours, F-37032, France.





Figure S1: TRPV2 has no effect on cancer cell viability and induces calcium cell migration **independently of calpain activity**. Induction of TRPV2 plasma membrane translocation by LPC and AD-HGPC in cancer cells. A. Tranilast (75 µM) and siTRPV2 have no effect on MDA-MB435s and MDA-MB231 cell viability. Histograms showing mean +/- SEM. Data were normalized to control condition (N=2,n=4). **B.** Fluorescence measurement and relative fluorescence to Ca<sup>2+</sup> entry in MDA-MB-231 cells cultured in medium with 40 mM KCl and 40 mM NaCl. Histograms show mean +/- SEM of ratiometric fluorescence. Data were normalized to conditions obtained with cells cultured in medium with 40mM NaCl (N=3, n=6 \*p < 0.05). C. Tranilast treatment (75µM) or TRPV2 knock-down are no effect on calpain activity, in MDA-MB231 cell line (N=3;n=6). **D.** Depolarisation induced by 40 mM KCl is involved in breast cancer cell migration. Histograms showing MDA-MB-231 cell migration in 40 mM of NaCl (control) or 40 mM KCl (mean +/- SEM, N=3, n=6 \*\*\*p < 0.001). **E.** AD-HGPC has no effect on MDA-MB-435s cell viability until 10  $\mu$ M (N=3). Cell viability is affected from 30 $\mu$ M F. LPC promoted constitutive Ca<sup>2+</sup> entry in MDA-MB-435 cells. Fluorescence measurement was preformed to characterize this Ca<sup>2+</sup> entry in cells treated by LPC (1 µM) and DMSO (control). Histograms show mean +/- SEM of ratiometric fluorescence. Data were normalized to conditions obtained with control condition (N=4, \*p < 0.05). **G.** AD-HGPC and LPC induced translocation of TRPV2 to the plasma membrane in MDA-MB-231 cells (Black line represents isotype used as negative control). Histograms show TRPV2 surface expression in MDA-MB-231 cells after acute application of LPC (1  $\mu$ M) or AD-HGPC (300 nM) (mean +/- SEM, N=4 \*p <0.05, \*\*p < 0.01).



**Figure S2: AD-HGPC induces cells migration by stimulating PI3K/Akt/girdin pathway and effect of Gelsolin's** *knock-down* **on cancer cells migration**. **A.** Inhibition of PI3K blocks the translocation of TRPV2 to the plasma membrane of HEK-hTRPV2 cells. The TRPV2 plasma membrane translocation induced by acute application of AD-HGPC is abolished by a pretreatment with LY294002) (mean +/- SEM, N=4 \*p < 0.05). **B.** The increase of recruitment of TRPV2 is inhibited by pharmacological inhibition of Akt signaling pathway by MK2206 (1 μM) on HEK-hTRPV2 cells (mean +/- SEM, N=3, \*p < 0.05, \*\*p < 0.01). **C.** Silencing of girdin inhibits cell migration effect induce by AD-HGPC and and do not modify Tranilast effect. Histograms represent the migration of MDA-MB-435s and MDA-MB-231 cells for 24 h transfected with siGirdin (mean +/- SEM, N=3, n=8-9 \*\*\*\*p < 0.0001). **D.** Gelsolin is involved in breast cancer cell migration. Histograms represent the migration of MDA-MB-435s and MDA-MB-435s and MDA-MB-231 cells for 24 h transfected with siGelsolin (mean +/- SEM, n=9 \*\*p < 0.01).